Tris Arscott, MD (@wtarscott) header
Tris Arscott, MD (@wtarscott) profile picture

Radiation oncologist and researcher. @CompassOncology. Tweets are my own

Portland, OR
Joined November 2012
Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)
Tris Arscott, MD retweeted
Randomized Trial adjuvant RT Keloids · 13 Gy sup control & aesthetic outcomes · 9 Gy reasonable low tension sites redjournal.org/article/S0360…
3
26
71
3,251
Tris Arscott, MD retweeted
During National Radiologic Technology Week, RSNA celebrates the dedicated radiologic technologists who help make exceptional patient care possible every day. Thank you for your skill, compassion and commitment to the profession. 💙 @ASRT #NRTW2026
1
9
2
17
1,701
Tris Arscott, MD retweeted
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging). Twittorial below Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)... 1/n
7
86
5
151
18,334
Tris Arscott, MD retweeted
Here is Version 2.0 of when to hold systemic tx during RT. Updated & w 3 additional drug categories (ADCs, CDK4/6 inhibitors, PARPi). More details on newer drugs in 🧵 below. Please use this version as reference & thanks for all input/experience crowdsourcing! (1/3)
Someone suggested I make a table summarizing the video. Here it is!
8
150
5
318
39,431
Tris Arscott, MD retweeted
🚫 SUPREMO Trial: Why It Does NOT Change PMRT Practice Today? 🔍 What SUPREMO actually tested? •Chest wall RT alone after mastectomy •Treatment era: 2006–2013 •All node-positive pts → full axillary dissection •Minimal regional nodal irradiation (RNI) 📉 Key findings •❌ No OS benefit overall •✅ Node-positive pts: lower locoregional recurrence with RT •Very low-risk cohort: •25% node-negative •41% only 1 micro/macro node •Just 3% chest-wall recurrence without RT 🎯 Why this doesn’t reflect 2025 practice? Modern PMRT → Chest wall + SCF + IMN (full RNI) SUPREMO → Chest wall only Modern surgery → Sentinel node biopsy SUPREMO → Full axillary dissection Modern systemic therapy → Genomic + biologic risk-driven SUPREMO → Older-era treatments 🧭 Real-world takeaway PMRT with RNI remains SOC for most pts with 1–3 positive nodes (ASTRO–ASCO–SSO 2024 guideline) 🧪 What’s coming next? MA.39 / TAILOR RT will clarify if low-burden node-positive + low Oncotype pts can omit PMRT. 📌 Bottom line SUPREMO ≠ Skip RT. It reflects old surgery + inadequate RT volume in a low-risk population. 📚 Citation Kunkler et al. NEJM. 2025. DOI: doi.org/10.1056/NEJMoaSUPREM… (ASTRO commentary: The ASCO Post, Nov 2025) #OncoTwitter #MedTwitter #BreastCancer #RadiationOncology #PMRT #ASTRO #ASCO @myESMO @esmo_open @ASCO @OncoAlert @ASTRO_org
🚨 NEJM SUPREMO Trial (2025): Do all mastectomy pts need chest-wall RT? 🧐 👩‍🔬 1,607 women with intermediate-risk breast cancer (pT1N1, pT2N1, or pT3NO or stage pT2NO with a histologic grade 3 or LVSI) randomized to: 🟦 Chest-wall RT (40–50 Gy) vs 🟩 No RT 📊 10-yr Results: 💀 OS: 81.4 % (RT) vs 81.9 % (No RT) → HR 1.04 🟰 NS 🧭 DFS: 76.2 % vs 75.5 % → NS 🧱 Chest-wall recurrence: 1.1 % vs 2.5 % (HR 0.45 ✅ ↓LRR) ⚡ Triple-negative: worse OS with RT (HR 1.9 ⚠️) 💬 Take-home: Modern systemic therapy = ultra-low local relapse 💊 👉 Omission of PMRT in intermediate-risk pts is now safe & rational ✅ 💡 Discuss this at your next Tumor Board! 🔖 Save + 📤 Share! 📚 Kunkler IH et al. N Engl J Med 2025 🔗 nejm.org/doi/full/10.1056/NE… #OncoTwitter #BreastCancer #RadiationOncology #MedTwitter @OncoAlert @myESMO @esmo_open @JCO_ASCO
2
28
92
14,473
Tris Arscott, MD retweeted
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO
18
354
82
806
220,433
Tris Arscott, MD retweeted
Can QUAD be used for thoracic tumours? 🟰YES! ➡️ 3 cycles of quad shot is safe and feasible with concurrent systemic therapy for centrally located thoracic tumours ➡️Limited grade 3 toxicities ➡️ Majority of patients experienced symptom relief as measured by PROs #ASTRO24
17
1
54
8,262
Tris Arscott, MD retweeted
Are you a PGY4/5? We invite you to apply for our 300in10, 2-month fellowship program focusing on advancing #brachy. This is an opportunity to immerse yourself in a community committed to training competent brachytherapists. bit.ly/4all3Fk @AndrewFarach @daniel_petereit
4
2
17
5,896
Tris Arscott, MD retweeted
🎙️ OPRA updated analysis confirms the long-term organ preservation with total neoadjuvant therapy for #rectalcancer ‼️@OncoAlert @ASCO 📌Ph2 trial w/ 👥random to induction CTH followed by CRT (INCT-CRT) or vice versa - Complete/near-complete responders were offered WW, incomplete responders ➡️🔪 🥇🎯: DFS. 🥈 🎯: TME-free survival 📊RESULTS -324 👥, median FU 5.1 y - 5-y DFS rates: INCT-CRT 71%, CRT-CNCT 69% (no sig) - TME-free survival: INCT-CRT 39%, CRT-CNCT 54% (P = .012) - 94% of regrowth within 2 y, 99% within 3 y - DFS similar for TME post-restaging and WW followed by TME post-regrowth (both 64%, N🚫 sig) #radonc ascopubs.org/doi/pdf/10.1200…
1
65
3
129
14,505
Grateful for our work examining the success of peer-to-peer authorization strategies highlighting @NCCN guideline-cited Level 1 evidence in reversing insurance denials for spine #SBRT being published in @AJCOonline! #KillCancer #FixPriorAuth #SPORTSMEN journals.lww.com/amjclinical…
1
4
2
22
4,907
Happy and proud to discuss results from ARTO trial results during XXXIII SIURO congress! @siuroIT
5
20
802
Tris Arscott, MD retweeted
IMPORT 10y: Late normal tissue effects at 10y ~5% in PBI arm vs ~30%(!!!!) in whole breast arm, and local control "better" with partial breast(!) Frankly, whole breast radiotherapy is the *wrong* tx for older women w/ early, low risk #breastcancer onclive.com/view/reduced-dos…
7
23
1,917
Tris Arscott, MD retweeted
💥First plenary #ASTRO23 @vinaigondi presented PCI +/- hippocampal avoidance for small cell lung cancer. 🧠 ⭐️HVLT-R no different (primary end point) ⭐️Did reduce first failure in any cognitive test (2nd endpoint) ⭐️No diff in intracranial failure 👏
4
4
619
Tris Arscott, MD retweeted
Comparison of all #radonc compared to Keytruda and Optdivo #medonc wow and look at the patient numbers too …
3
4
7
1,255
Tris Arscott, MD retweeted
#ASTRO2023 Hippocampal avoidance in PCI for SCLC, randomized phase III NRG C003 👉No increased risk of BM development 👉23% reduction risk to first cognitive failure ❓Durable effect
1
40
96
7,109
Tris Arscott, MD retweeted
🔥🔥☢️PACE-B results #ASTRO23 @nickva1 Conventional RT (78/39 or 62/20) vs SBRT (36.25/5 + 40 CTV) for IR (90%) prostate cancer ⭐️Freedom from clinical/biochemical failure 95% conv vs 96% SBRT ⭐️No diff in RTOG GI/GU tox ⭐️Did note inc G1/2 GU tox on CTCAE at early timepts
14
30
3,433
Tris Arscott, MD retweeted
Can we opt for SRS rather than WBRT for small cell lung cancer brain metastases? Initial results from ARO 2018-9 presented by Dr. Rinaa Puglia at #ASTRO23 ⭐️less decline in cognition (HVL-T) ⭐️similar OS ( but short 6 mo follow up) ⭐️Other endpoints pending
1
22
1
32
3,945
Tris Arscott, MD retweeted
Does vaginal dilation/regular sex improve outcomes after pelvic radiation? EMBRACE data presented by Dr. Kirchheiner at #ASTRO23 ⭐️Reduced vaginal stenosis w/ dilator use/sex ⭐️Doing both seemed better than either alone ⭐️Did inc vaginal dryness/bleeding but tx options for this
1
23
3
53
5,067
Tris Arscott, MD retweeted
🔥🔥🔥 Hey #GIonc #Radonc friends- rectal cancer management is evolving rapidly. Let’s run through a case-based review of rectal cancer!!! #ASTRO23
6
46
7
118
34,072
Tris Arscott, MD retweeted
🎙️ #SBRT is an effective treatment modality for #HCC patients with mature follow up❗️@OncoAlert @IJROBP congrats @DrAlexLouie 📌SR & MA on outcomes and hepatic toxicity rates after SBRT for liver-confined HCC 📊RESULTS 👉17 observational 📝 w/ 1889 👥 👉3-y OS SBRT: 57% (CI: 47-66%) 👉5-y OS SBRT: 40% (CI: 29-51%) 👉3-y LC SBRT: 84% (CI: 77-90%) 👉5-y LC SBRT: 82% (CI: 74-88%). 👉T size 🔄 LC &OS 👉⬆️OS T <3 cm, eastern region, CP ≤B7 #radonc #hcc #surgery #gastroenterology doi.org/10.1016/j.ijrobp.202…
22
47
3,858